ArticleThe Journal of biological chemistry2011
Protection of neuronal calcium sensor 1 protein in cells treated with paclitaxel.
Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Chemotherapy-induced peripheral neuropathy in breast cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Monomethyl auristatin E and paclitaxel use different mechanisms to alter intracellular calcium signaling.Biochemical pharmacology · 2025Article
- Measuring symptoms and toxicities: a 35-year experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Review
- Functional Interaction between Transient Receptor Potential V4 Channel and Neuronal Calcium Sensor 1 and the Effects of Paclitaxel.Molecular pharmacology · 2021Article
- Pharmacological rescue of cognitive function in a mouse model of chemobrain.Molecular neurodegeneration · 2021Article
- Comprehensive somatosensory and neurological phenotyping of NCS1 knockout mice.Scientific reports · 2021Article
- Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings.Critical reviews in oncology/hematology · 2020Review
- Characterization of NCS1-InsP3R1 interaction and its functional significance.The Journal of biological chemistry · 2019Article
- NCS-1 is a regulator of calcium signaling in health and disease.Biochimica et biophysica acta. Molecular cell research · 2018Review
- Article
- Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival.Molecular cancer research : MCR · 2017Article
- Article
- Neuronal Calcium Sensor 1 Has Two Variants with Distinct Calcium Binding Characteristics.PloS one · 2016Article
- Inhibition of paclitaxel-induced decreases in calcium signaling.The Journal of biological chemistry · 2012Article
- Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2012Article
- Multiple roles for frequenin/NCS-1 in synaptic function and development.Molecular neurobiology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Paclitaxel (Taxol) is one of the most effective treatment options for patients suffering from a variety of cancers. A major side effect seen in a high percentage of patients treated with paclitaxel is irreversible peripheral neuropathy. We previously reported that prolonged treatment with paclitaxel activates a calcium-dependent enzyme, calpain, which degrades neuronal calcium sensor 1 (NCS-1) and subsequent loss of intracellular calcium signaling. Because it appears that activation of calpain is an early step in this destructive cascade, we proposed that inhibition of calpain will protect against the unwanted side effects of paclitaxel treatment. First, NCS-1 levels and intracellular calcium signaling were found to be protected by the presence of lactacystin, a protesome inhibitor. To reinforce the role of calpain in this process, we showed that increased concentrations of calpastatin, a naturally occurring calpain inhibitor, were protective. Next, we tested two mutated versions of NCS-1 developed with point mutations at the P2 position of the calpain cleavage site of NCS-1 to decrease the likelihood of NCS-1 degradation. One mutant was cleaved more favorably by calpain compared with NCS-1 WT, whereas the other mutant was less favorably cleaved. Expression of either mutated version of NCS-1 in neuroblastoma cells protected intracellular calcium signals from paclitaxel-induced changes. These results support our hypothesis that it is possible to protect cells from paclitaxel-induced degradation of NCS-1 by inhibiting calpain activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.